220 related articles for article (PubMed ID: 24957886)
41. Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition.
Obdeijn IM; Loo CE; Rijnsburger AJ; Wasser MN; Bergers E; Kok T; Klijn JG; Boetes C
Breast Cancer Res Treat; 2010 Jan; 119(2):399-407. PubMed ID: 19876732
[TBL] [Abstract][Full Text] [Related]
42. Should axillary ultrasound be used in patients with a preoperative diagnosis of ductal carcinoma in situ?
Ansari B; Boughey JC; Adamczyk DL; Degnim AC; Jakub JW; Morton MJ
Am J Surg; 2012 Sep; 204(3):290-3. PubMed ID: 22749764
[TBL] [Abstract][Full Text] [Related]
43. Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation.
Solin LJ; McCormick B; Recht A; Haffty BG; Taylor ME; Kuske RR; Bornstein BA; McNeese M; Schultz DJ; Fowble BL; Barrett W; Yeh IT; Kurtz JM; Amalric R; Fourquet A
Cancer J Sci Am; 1996; 2(3):158-65. PubMed ID: 9166516
[TBL] [Abstract][Full Text] [Related]
44.
Zhang Z; Wang H; Jin Y; Zhou J; Chu C; Tang F; Zou L; Zou Q
Biomark Med; 2023 Jun; 17(12):553-562. PubMed ID: 37814985
[No Abstract] [Full Text] [Related]
45. Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer.
Wang-Johanning F; Li M; Esteva FJ; Hess KR; Yin B; Rycaj K; Plummer JB; Garza JG; Ambs S; Johanning GL
Int J Cancer; 2014 Feb; 134(3):587-95. PubMed ID: 23873154
[TBL] [Abstract][Full Text] [Related]
46. A comparison of clinical-pathological characteristics between symptomatic and interval breast cancer.
Meshkat B; Prichard RS; Al-Hilli Z; Bass GA; Quinn C; O'Doherty A; Rothwell J; Geraghty J; Evoy D; McDermott EW
Breast; 2015 Jun; 24(3):278-82. PubMed ID: 25771080
[TBL] [Abstract][Full Text] [Related]
47. Mammographic density and risk of second breast cancer after ductal carcinoma in situ.
Habel LA; Capra AM; Achacoso NS; Janga A; Acton L; Puligandla B; Quesenberry CP
Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2488-95. PubMed ID: 20929881
[TBL] [Abstract][Full Text] [Related]
48. Nonpalpable breast cancer.
Bunnell DH; Bassett LW; Eggerding F; Steckel R
Am Fam Physician; 1987 May; 35(5):147-51. PubMed ID: 3034014
[TBL] [Abstract][Full Text] [Related]
49. [Visibility in ultrasonography as the strongest invasion predictor in ductal carcinoma in situ in a retrospective study].
Vrtelová P; Coufal O; Pavlík T; Bazout M; Fait V
Klin Onkol; 2009; 22(6):278-83. PubMed ID: 20099746
[TBL] [Abstract][Full Text] [Related]
50. Mammographic morphology and distribution of calcifications in ductal carcinoma in situ diagnosed in organized screening.
Hofvind S; Iversen BF; Eriksen L; Styr BM; Kjellevold K; Kurz KD
Acta Radiol; 2011 Jun; 52(5):481-7. PubMed ID: 21498306
[TBL] [Abstract][Full Text] [Related]
51. The value of sentinel lymph node biopsy in ductal carcinoma in situ (DCIS) and DCIS with microinvasion of the breast.
van la Parra RF; Ernst MF; Barneveld PC; Broekman JM; Rutten MJ; Bosscha K
Eur J Surg Oncol; 2008 Jun; 34(6):631-5. PubMed ID: 17851019
[TBL] [Abstract][Full Text] [Related]
52. Biennial versus annual mammography and the risk of late-stage breast cancer.
White E; Miglioretti DL; Yankaskas BC; Geller BM; Rosenberg RD; Kerlikowske K; Saba L; Vacek PM; Carney PA; Buist DS; Oestreicher N; Barlow W; Ballard-Barbash R; Taplin SH
J Natl Cancer Inst; 2004 Dec; 96(24):1832-9. PubMed ID: 15601639
[TBL] [Abstract][Full Text] [Related]
53. Extensive pure ductal carcinoma in situ of the breast: identification of predictors of associated infiltrating carcinoma and lymph node metastasis before immediate reconstructive surgery.
Guillot E; Vaysse C; Goetgeluck J; Falcou MC; Couturaud B; Fitoussi A; Fourchotte V; Laki F; Malhaire C; Sigal-Zafrani B; Sastre-Garau X; Bollet MA; Mosseri V; Reyal F
Breast; 2014 Apr; 23(2):97-103. PubMed ID: 24388733
[TBL] [Abstract][Full Text] [Related]
54. [In situ ductal carcinoma of the breast: a diagnostic challenge].
Fuchsjäger MH; Helbich TH
Wien Med Wochenschr Suppl; 2002; (113):69-73. PubMed ID: 12621847
[TBL] [Abstract][Full Text] [Related]
55. Shotgun proteomics coupled to nanoparticle-based biomarker enrichment reveals a novel panel of extracellular matrix proteins as candidate serum protein biomarkers for early-stage breast cancer detection.
Fredolini C; Pathak KV; Paris L; Chapple KM; Tsantilas KA; Rosenow M; Tegeler TJ; Garcia-Mansfield K; Tamburro D; Zhou W; Russo P; Massarut S; Facchiano F; Belluco C; De Maria R; Garaci E; Liotta L; Petricoin EF; Pirrotte P
Breast Cancer Res; 2020 Dec; 22(1):135. PubMed ID: 33267867
[TBL] [Abstract][Full Text] [Related]
56. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis.
Blixt O; Bueti D; Burford B; Allen D; Julien S; Hollingsworth M; Gammerman A; Fentiman I; Taylor-Papadimitriou J; Burchell JM
Breast Cancer Res; 2011 Mar; 13(2):R25. PubMed ID: 21385452
[TBL] [Abstract][Full Text] [Related]
57. Early diagnosis of breast cancer from exhaled breath by gas chromatography-mass spectrometry (GC/MS) analysis: A prospective cohort study.
Zhang Y; Guo L; Qiu Z; Lv Y; Chen G; Li E
J Clin Lab Anal; 2020 Dec; 34(12):e23526. PubMed ID: 33150682
[TBL] [Abstract][Full Text] [Related]
58. Aberrant reduction of telomere repetitive sequences in plasma cell-free DNA for early breast cancer detection.
Wu X; Tanaka H
Oncotarget; 2015 Oct; 6(30):29795-807. PubMed ID: 26356673
[TBL] [Abstract][Full Text] [Related]
59. Classifying patients for breast cancer by detection of autoantibodies against a panel of conformation-carrying antigens.
Evans RL; Pottala JV; Egland KA
Cancer Prev Res (Phila); 2014 May; 7(5):545-55. PubMed ID: 24641868
[TBL] [Abstract][Full Text] [Related]
60. Calponin-h2: a potential serum marker for the early detection of human breast cancer?
Debald M; Jin JP; Linke A; Walgenbach KJ; Rauch P; Zellmer A; Fimmers R; Kuhn W; Hartmann G; Walgenbach-Brünagel G
Tumour Biol; 2014 Nov; 35(11):11121-7. PubMed ID: 25099617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
